Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingBusiness Wire • 09/27/23
Adicet Reports Second Quarter 2023 Financial Results and Provides Business UpdatesBusiness Wire • 08/09/23
Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth ConferenceBusiness Wire • 08/02/23
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Business Wire • 06/26/23
Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare ConferenceBusiness Wire • 06/01/23
Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual MeetingBusiness Wire • 05/18/23
Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/10/23
Adicet Reports First Quarter 2023 Financial Results and Provides Business UpdatesBusiness Wire • 05/09/23
Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual ConferenceBusiness Wire • 04/13/23
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company ProgressBusiness Wire • 03/15/23
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology ConferenceBusiness Wire • 02/01/23
Down -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET)Zacks Investment Research • 12/30/22
Adicet Bio, Inc. (ACET) Loses 47% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 12/14/22
Adicet Bio shares fall as it shares clinical data about its CAR-T treatment candidateMarket Watch • 12/12/22
What Makes Adicet Bio, Inc. (ACET) a Good Fit for 'Trend Investing'Zacks Investment Research • 12/07/22
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Business Wire • 12/02/22